Day 2: PARASOL APOL1 & MN Kickoff

The October 10 sessions of the PARASOL kickoff meeting for APOL1 kidney disease and membranous nephropathy (MN) projects continued the conversation between leading nephrologists, clinical trialists, and researchers on strategies to address regulatory biomarkers and endpoints in APOL1 kidney disease, and primary membranous nephropathy. The mission of the PARASOL initiative is to accelerate the development of effective therapies and improve outcomes for patients with rare and complex kidney diseases. Its new membranous nephropathy project will explore the potential for aPLA2R to be used as a surrogate endpoint in clinical trials and a qualitative marker for monitoring disease severity, as well as expanding the data-driven understanding of other potential proteinuria-based endpoints for PMN trials. The focus of the APOL1 kidney disease project is to advance understanding of potential proteinuria-based surrogate endpoints for use in clinical trials in APOL1 kidney disease.